Organotypic spinal cord culture in serum-free fibrin gel: a new approach to study three-dimensional neurite outgrowth and of neurotoxicity testing: Effects of modulating the actin and tubulin dynamics and protein kinase activities.
Spinal cord explants from embryonic day seven (E7) chicken embryos were cultured without serum and in the presence of aprotinine, in a three-dimensional fibrin matrix. These conditions promote a robust, radial, unfasciculated outgrowth of neurites that are tipped by elaborate growth cones. Routinely after 5 days, the neurite outgrowth intensity (NOI) was determined by measuring the optical density of the immunostained neurites (image analysis program OPTIMAS version 5.2) within defined areas, extending radially for up to 3 mm from the explant border. A dose-dependent inhibition of NOI was determined for the cytoskeleton-affecting drugs nocodazole (half maximal inhibition ([I50]), 0.02 microM), taxol ([I50], 0.016 microM), cytochalasin D ([I50], 0.006 microM), and tetramethyl lead ([I50], 0.05 microM). Likewise, NOI was decreased in a dose-dependent fashion by ML-9 and RO-31-8220, inhibitors of myosin-light chain kinase and protein kinase C (PKC), respectively. The addition of 1,2-dioctanoyl-s,n-glycerol, a potent activator of PKC, led, at 5 microM, to an increase and at 30 and 60 microM to a decrease in NOI. The described system provides a rapid, reproducible, and quantitative assay for the effects of exogenous factors on the mode and intensity of neurite outgrowth.
Rösner
H
H
Institute of Zoology, University of Hohenheim-Stuttgart, Stuttgart, Germany. roesnerh@uni-hohenheim.de
Vacun
G
G
D000199:Actins / Q000378:metabolism*; D000818:Animals; D007611:Aprotinin / Q000494:pharmacology; D001381:Azepines / Q000494:pharmacology; D002642:Chick Embryo; D015638:Cytochalasin D / Q000494:pharmacology; D003720:Densitometry / Q000379:methods; D004075:Diglycerides / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005337:Fibrin; D005782:Gels; D007211:Indoles / Q000494:pharmacology; D016501:Neurites / Q000187:drug effects / Q000502:physiology* / Q000648:ultrastructure; D009498:Neurotoxins / Q000494:pharmacology*; D015739:Nocodazole / Q000494:pharmacology; D009924:Organ Culture Techniques; D017239:Paclitaxel / Q000494:pharmacology; D011494:Protein Kinases / Q000378:metabolism; D013116:Spinal Cord / Q000166:cytology / Q000502:physiology*; D013756:Tetraethyl Lead / Q000031:analogs & derivatives / Q000494:pharmacology; D014404:Tubulin / Q000378:metabolism*
D000199:Actins; D001381:Azepines; D004075:Diglycerides; D004791:Enzyme Inhibitors; D005782:Gels; D007211:Indoles; D009498:Neurotoxins; D014404:Tubulin; C056218:ML 9; C044295:1,2-dioctanoylglycerol; D013756:Tetraethyl Lead; D015638:Cytochalasin D; D005337:Fibrin; D007611:Aprotinin; C014849:tetramethyllead; D011494:Protein Kinases; D017239:Paclitaxel; D015739:Nocodazole; C064758:Ro 31-8220